Ikena Oncology Inc expected to post a loss of 43 cents a share - Earnings Preview

ImageneBio

03/11/2023 18:56

* Ikena Oncology Inc  IKNA.OQ   IKNA.O  is expected to show
a fall
in quarterly revenue when it reports  results 
    * The Boston Massachusetts-based  company is expected to
report  a
60.2% decrease in revenue to $2.548 million from $6.4 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Ikena Oncology Inc
is for
a loss of 43 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ikena
Oncology
Inc is $18​, above​ its last closing price of $4.06. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.46       -0.47      -0.44     Beat    7.3
 Mar. 31 2023  -0.47       -0.47      -0.39     Beat    16.6
 Dec. 31 2022  -0.53       -0.48      -0.40     Beat    16.1​
 Sep. 30 2022  -0.48       -0.50      -0.48     Beat    3.1
 ​​Jun.        -0.47       -0.49      -0.57     Missed  -16.8
 30 2022                                                
 Mar. 31 2022  -0.40       -0.42      -0.47     Missed  -12.4​
 Dec. 31 2021  -0.57       -0.51      0.07      Beat    113.7
 Sep. 30 2021  -0.41       -0.42      -0.40     Beat    4.8
 This summary was machine generated November 3 at 18:56 GMT.  All
figures in US dollars  unless otherwise stated